• About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

About

OKYO Pharma Ltd. (LSE:OKYO, NASDAQ:OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is developing a lipidated chemerin-peptide drug candidate OK-101, designed to target a key ocular receptor controlling inflammation and ocular pain. The drug, developed by a unique proprietary membrane anchored technology, is designed to increase agonist potency and ocular residence time.

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

© OKYO Pharma, Limited | 2022

Explore

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Follow

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Legal

  • Legal
  • Privacy Policy
MENU
  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact